BioSpace News Archive

FreeStyle Libre 2 is the only integrated continuous glucose monitoring (iCGM) system available that continuously transmits glucose data every minute with customizable, optional real-time alarms to alert users when their glucose is high or low without scanning

MedX Health Corp. announces that it has signed an Exclusive Distribution Agreement with EMC LABS, S.A.P.I. DE C.V., operating as MedX Mexico, which plans to launch an aggressive ease-of-access skin scanning/assessment program throughout Mexico, using MedX’s SIAscopy on DermSecure™ Telemedicine platform.

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it has successfully accelerated the development of its Container Closure Integrity test– an essential component of the Stability Test required by the U.S. Food and Drug Administration.

IMV Inc., is pleased to announce that Institutional Shareholder Services Inc. and Glass, Lewis & Co., LLC, have recommended that shareholders vote FOR all of the items submitted for shareholder approval at this year’s Annual and Special Meeting of Shareholders.

Treos Bio Limited, a clinical stage biopharma company developing targeted peptide cancer immunotherapies, said that it has developed and successfully tested in silico a preventive COVID-19 peptide vaccine and has transferred all rights, including pending patent applications, to a newly formed subsidiary, PepTC Vaccines Limited.

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that effective today it has appointed Andrei Floroiu as Chief Executive Officer.

Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to provide updates regarding data from the Phase I study of SLS-002 on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also provide an overview of the design for Seelos’ next study of SLS-002 for Acute

Motus GI Holdings, Inc. announced that physicians and hospitals using the Pure-Vu® System will now have on-demand access to a full spectrum of Motus support and educational resources via the new Motus GI mobile app, which was launched.

SOTIO, a clinical stage immuno-oncology company and Cytune Pharma, both owned by PPF Group, announced that they will present new preclinical data on SO-C101, an IL-15 superagonist currently being studied in a Phase 1 trial

Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl June, M.D., as Chairman of its newly formed Scientific Advisory Board (SAB). Dr. June is recognized in the oncology field for his groundbreaking work in the development and commercialization of gene therapy and T-cell therapies. The SAB will provide strategic counsel to guide the efficient develo